Gilead Sciences, Inc GILD

NASDAQ US Health Care Biotechnology

$130.21 ▼ -0.82% ($-1.07)

Index member: S&P 500

⬆️ Above Yest. High 📅 Earnings This Week

Open $130.23

Prev Close $131.28

Day Range $128.76 – $130.89

52W Range $108.46 – $157.29

Market Cap $161.66B

P/E (TTM) 17.55

Beta 0.34

Div Yield 2.50%

EPS (TTM) $7.35

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1992-01-22
Shares Out.	1,241,570,000
Website	gilead.com ↗
Phone	13026587581
Employees	17,000
Revenue	$6.96B
Gross Profit	$5.52B
Net Income	$2.02B
Free Cash Flow	$10.23B
Total Assets	$56.28B
Total Liabilities	$32.85B
Equity	$23.43B

About Gilead Sciences, Inc

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences, Inc is a publicly traded company under the ticker symbol GILD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.